Clinical trial NCT00472225: Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Official title: Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Steroid-Refractory Chronic GVHD
Keywords: Chronic graft-versus-host disease
rituximab
Lead sponsor: The Korean Society of Hematopoietic Stem Cell Transplantation
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2007-05-11
Enrollment: 42
Sex: ALL
Minimum age (years): 3
Maximum age (years): 74
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic immunodeficiency etc. Thus, chronic GVHD can lead to debilitating complications such as joint contractures, blindness, end-stage lung disease, etc so that chronic GVHD has a major impact both on survival as well as quality of life. Although its pathogenesis is still poorly unclear, it has been reported since 2000 that B cell-mediated immunity may also contribute to development of chronic GVHD other than T cells. Thus, targeting against B cell may be a useful treatment strategy in the treatment of chronic GVHD.

The purpose of this study is to determine whether rituximab, an anti-CD20 monoclonal kimeric antibody is effective in the treatment of chronic graft-versus-host disease (chronic GVHD) refractory to steroid.

Detailed description: 1. STUDY OBJECTIVES

   * Primary Endpoints: To assess the response rate
   * Secondary End points

     * To evaluate the discontinuation of corticosteroid
     * To assess the quality of life
2. Treatment schedule

   * The BSA on the date of every treatment cycle may be used as the same value of baseline BSA, if change of body weight is within 10% of baseline body weight.
   * Treatment schedule consists of induction and maintenance therapy as follows

     * Induction - Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks
     * Maintenance - Rituximab 375 mg/m2 monthly IV for 4 consecutive months

Eligibility criteria: Inclusion Criteria:

* All recipients underwent allogeneic stem cell transplantation for haematologic disorders
* All recipients diagnosed as chronic GVHD according to diagnostic criteria proposed by National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD

  * The presence of one diagnostic sign Or
  * The presence of one distinctive sign (Appendix 1B) with laboratory or histopathologic confirmation in the same or other organ if diagnostic feature is not present
* All patients with chronic GVHD have at least moderate score based on the global scoring system of chronic GVHD
* Recipients refractory or resistant to therapy with corticosteroid

  * Patients had chronic GVHD with the same severity during the last one month while they had received the equivalent of prednisone ≥0.5mg/kg per day or 1mg/kg every other day at least for 30 days or longer
* Informed consent
* Other concomitant medication

  * Patients treated with other immunosuppressive agents (cyclosporine, thalidomide etc) as a combination therapy with corticosteroid must be receiving a dosage that has been stable for at least 1 month prior to screening.

Exclusion Criteria:

* Recipients received donor lymphocyte infusions in the preceding 100 days
* Serious comorbid diseases
* Life expectancy of less than 1 month
* Age \< 2 years and \> 75 years
* Pregnant or intended to become pregnant
* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy

Primary outcomes:
measure: Complete response (CR) : Resolution of all signs and symptoms of chronic GVHD Partial response (PR) : Improvement (at least 1 clinical score reduction) in 1 or more organs of involvement and no evidence of worsening in any organ
timeFrame: Response evaluation will be perfomed every 4 weeks during the maintenance of rituximab (the 12th, 16th, 20th, 24st, 36th and 52th week).
Secondary outcomes:
measure: Steroid tapering
timeFrame: Within one year after start the first dose of rituximab
measure: Quality of life
timeFrame: Baseline, the 8th and 52th week.
measure: Toxicity
timeFrame: 1 year
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungpook University Hospital
state: Kyungsang-do
city: Busan
country: Korea, Republic of
facility: Busan Baik Hospital
city: Busan
country: Korea, Republic of
facility: Busan National University Hospital
city: Gwangju
country: Korea, Republic of
facility: Chun Nam National University Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University
city: Seoul
country: Korea, Republic of
facility: Soon Chun Hyang Hospital
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea
city: Seoul
country: Korea, Republic of
facility: Yonsei University Hospital
Study officials:
affiliation: Soon Chun Hyang Hospital, Seoul, Korea
name: Jong-Ho Won, MD
role: PRINCIPAL_INVESTIGATOR
References: